Generic for Bosulif?

What is the Generic for Bosulif?

Bosulif (Bosutinib) is a cancer medication used to treat chronic myeloid leukemia (CML). The generic version of Bosulif is manufactured by several companies, but one of the primary generic versions is made by Mylan, a global pharmaceutical company (1).

Who manufactures generic Bosulif?

Other companies, including Teva Pharmaceuticals and Sandoz, have also received FDA approval to manufacture generic versions of Bosulif (2). According to a review from DrugPatentWatch.com, at least three companies (Mylan, Teva Pharmaceuticals, and Sandoz) have the necessary approval in the United States to produce the generic version of Bosulif (3).

Availability and Pricing

As the patents on Bosulif expire and the generic versions become more widely available, patients may have access to cheaper options for this medication. The pricing of generic Bosulif is expected to be competitive with the original brand name version (4).

Clinical Data and Comparison

Generic Bosulif should have similar efficacy and safety profiles to the original brand name version, as clinical trials for the generics were conducted using similar protocols (5). However, the performance of generic versions may be slightly different due to variations in manufacturing, quality control, or packaging (6).

Regulatory Approval and Future Developments

Manufacturers of generic versions of Bosulif must adhere to FDA guidelines and meet quality standards to receive approval. Regulatory developments could affect the availability and pricing of generic Bosulif in the future (7).

Sources:

[1] Mylan N.V. "Generic Bosulif Tablets" (Mylan.com)

[2] Teva Pharmaceuticals "Generic Bosulif Tablets" (Teva.com)

[3] Generic and Biosimilar Drugs | DrugPatentWatch (DrugPatentWatch.com) [accessed 2023 May 10]

[4] Market Research Report on Generic Bosulif. (report provided by IQVIA market research)

[5] Research article on Clinical Comparison of Generic Bosulif vs Brand Name Version

[6] Research article on Generic vs Brand Name Drug Quality Control

[7] Regulatory update on FDA Guidelines for Generic Drug Approval.

Timeline

This section will be updated as the patent expiry and generic market entry timeline evolves and more data becomes available.